NeuraLight

NeuraLight develops an AI-powered platform that uses advanced computer vision and machine learning to capture and analyze oculometric measures — dozens of precise eye movement patterns — as objective digital biomarkers of brain function. These biomarkers provide clinical insights into neurological conditions including Parkinson's disease, ALS, multiple sclerosis, and other CNS disorders, enabling more accurate disease monitoring and drug efficacy measurement in clinical trials. The company has published peer-reviewed research in leading neurology journals and has established clinical partnerships with leading medical centers worldwide, including a collaboration with Teitur Trophics for Parkinson's disease trials. Founded in 2021 in Tel Aviv, NeuraLight bridges the gap between traditional clinical assessment and objective, continuous measurement of neurological function.